A biomedical startup that focuses on implant technology and stem cell therapies has raised $7.4 million, according to a Securities and Exchange Commission filing.
Vivex Biomedical Inc. is developing implant technology to help stimulate bone regrowth. Vivex has also licensed a highly adaptive adult stem cell line, known as MIAMI (Marrow Isolated Adult Multi-lineage Inducible) cells.
With its implant and stem cell technology, Vivex plans to target patients with spinal cord injuries, orthopedic injuries and traumatic wounds.
Stem cells migrate to areas of injury and then transform into differentiated cells that help support the matrix for repairing and regenerating bone, cartilage and nerves. Vivex’s MIAMI cells are more robust than typical bone marrow stem cells.
Unlike typical bone marrow stem cells, MIAMI cells don’t trigger inflammation, which can slow down the healing process. MIAMI cells are especially effective for patients who heal more slowly because of unrelated medical conditions such as diabetes, poor circulation and previous surgery.
Vivex is also developing an electrically conductive surface on polymer implants traditionally used in spinal surgery. The electrically conductive surface, known as a mimetic surface, helps stimulate new cells to form on the implant, helping bone grow faster.
The technology will initially be used for spine fusion — treating people with degenerative disc disease who suffer chronic pain. Vivex hopes to have its implant and stem cell therapy on the market by early 2014.
Published at Atlanta Business Chronicle